0000000000974256

AUTHOR

Sven Starke

showing 1 related works from this author

Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies

2013

Background: Phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS) is caused by germ line mutations in the PTEN gene. Symptoms include cancer pre- disposition, immune deviations, and lipomas/lipomatosis. No causal standard therapy is available. We describe a therapeutic attempt with the mammalian target of rapamycin (mTOR) inhibitor sirolimus for a PHTS patient suffering from thymus hyperplasia and lipomatosis. We furthermore assessed the in vitro effects of sirolimus and other inhibitors on lipoma cells of the patient. Methods: The patient underwent clinical and blood examinations and whole-body magnetic resonance imaging to assess tumor sizes. Lipoma cells of the patient we…

LipomatosisIn Vitro TechniquesDrug therapy Hamartoma Paediatrics PTEN PHTS PI3K AKT mTORmedicineHumansTensinPTENddc:610Protein kinase BPI3K/AKT/mTOR pathwaySirolimusbiologybusiness.industryInfant NewbornPTEN PhosphohydrolaseInfantLipomamedicine.diseaseChild PreschoolSirolimusPediatrics Perinatology and Child HealthCancer researchbiology.proteinThymus hyperplasiaHamartoma Syndrome Multiplebusinessmedicine.drugPediatric Research
researchProduct